Sponsor Dossier
Mayne Pharma
Sponsor Dossier for Mayne Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACTIKERALL
- Brand: ASTRIX
- Brand: Budesonide
- Brand: Carbidopa
- Brand: Diltiazem
- Brand: DORYX
- Brand: Eryc
- Brand: FABIOR
- Device (sponsor): Epidermal osmotic dressing, non-sterile
- Device (sponsor): Lice treatment solution, natural
- Device (manufacturer): Irrigation kit, <specify>
- Device (manufacturer): Irrigation fluid, nasal
- Device (manufacturer): Irrigation kit, <specify>
About
Mayne Pharma is an Australian Private Company with ABN 88007870984, registered in South Australia. The entity is active and registered for GST from 1 July 2000.
Portfolio
Mayne Pharma's ARTG portfolio comprises 22 brands, of which 14 are indexable. Eleven brands have Product Information on file, six brands have PBAC outcomes on record, and one brand has an AusPAR on record. Notable brands include ACTIKERALL, ASTRIX, Budesonide, Carbidopa, Diltiazem, DORYX, Eryc, FABIOR, KADIAN, KAPANOL, LOZANOC, and Magnoplasm.
Therapeutic focus —
Dermatology: 5 brands — Complementary Medicine: 4 brands — Infectious Disease: 3 brands — Oncology: 2 brands — Neurology: 2 brands — Urology: 2 brands — Ophthalmology: 1 brand — Cardiology: 1 brand — Pain Management: 1 brand — Reproductive Health: 1 brand
PBS footprint
Five brands in the Mayne Pharma portfolio are PBS-listed, with the most recent schedule date of 1 May 2026.
Regulatory activity
Mayne Pharma's latest PBAC outcome was recorded on 1 March 2025, with six brands holding PBAC outcomes on record. The most recent AusPAR dates to 18 May 2017, with one brand holding an AusPAR on record.